Results
1
-
10
of
127
<
1
2
3
...
12
13
>
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW.
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
,
AIDS research and therapy
[PubMed: 29096670]
[DOI: 10.1186/s12981-017-0185-4]
Salvaggio SE; Giacomelli A; Falvella FS; Oreni ML; Meraviglia P; Atzori C; Clementi EGI; Galli M; Rusconi S.
Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.
,
BMC infectious diseases
[PubMed: 28583112]
[DOI: 10.1186/s12879-017-2497-3]
Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T.
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
,
The patient
[PubMed: 26286337]
[DOI: 10.1007/s40271-015-0137-9]
Brunetta J; Moreno Guill?n S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S.
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
,
The patient
[PubMed: 25808940]
[DOI: 10.1007/s40271-015-0123-2]
Deeks ED.
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
,
Drugs
[PubMed: 25352394]
[DOI: 10.1007/s40265-014-0318-1]
Papakonstantinou VD; Chini M; Mangafas N; Lazanas MC; Stamatakis GM; Tsogas N; Tsoupras AB; Psarra K; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA.
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
,
Lipids in health and disease
[PubMed: 24884881]
[DOI: 10.1186/1476-511X-13-90]
Lu C; Jia Y; Yang J; Song Y; Liu W; Ding Y; Sun X; Wen A.
Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.
,
Clinical drug investigation
[PubMed: 22413748]
[DOI: ]
Dakin H; Sherman M; Fung S; Fidler C; Bentley A.
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
,
PharmacoEconomics
[PubMed: 22077579]
[DOI: 10.2165/11589260-000000000-000]
Palacios R; Hidalgo C; R?os MJ; Rivero A; Mu?oz L; Lozano F; Guti?rrez-Rav? V; G?lvez MC; del Arco A; Santos J.
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
[PubMed: 18841401]
[DOI: 10.1007/s10096-008-0636-x]
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S.
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
,
European journal of clinical pharmacology
[PubMed: 17665183]
[DOI: 10.1007/s00228-007-0344-y]
<
1
2
3
...
12
13
>